BACKGROUND: In addition to its anticoagulant properties, heparin has anti-inflammatory effects, the molecular and mechanistic bases of which are incompletely defined. AIMS: The current studies were designed to test the hypothesis that heparin abrogates the expression or function of leucocyte-endothelial adherence molecules which are fundamental to the acute inflammatory response. METHODS: The effects of heparin on tumour necrosis factor alpha (TNF-alpha) induced leucocyte rolling, adhesion, and migration as well as vascular permeability were assessed in rat mesenteric venules using intravital microscopy. Expression of adhesion molecules was quantitated using a double radiolabelled monoclonal antibody (mAb) binding technique in vivo (P-selectin, intercellular cell adhesion molecule type 1 (ICAM-1), and vascular cell adhesion molecule 1 (VCAM-1)) or flow cytometry (CD11a, CD11b, and L-selectin). Ex vivo binding of heparin to neutrophils was assessed by flow cytometry. RESULTS: TNF-alpha induced a significant increase in leucocyte rolling, adhesion, and migration, and vascular permeability, coincident with a significant increase in expression of P-selectin, ICAM-1, and VCAM-1. Ex vivo assessment of blood neutrophils showed significant upregulation of CD11a and CD11b and significant downregulation of L-selectin within five hours of TNF-alpha administration. Heparin pretreatment significantly attenuated leucocyte rolling, adhesion, and migration but did not affect expression of cell adhesion molecules or vascular permeability elicited by TNF-alpha administration. Binding of heparin was significantly increased on blood neutrophils obtained five hours after TNF-alpha administration. Preincubation with an anti-CD11b mAb but not with an anti-CD11a or anti-L-selectin antibody significantly diminished heparin binding ex vivo. CONCLUSIONS: Our results support the concept that the anti-inflammatory effects of heparin involve attenuation of a CD11b dependent adherent mechanism.
BACKGROUND: In addition to its anticoagulant properties, heparin has anti-inflammatory effects, the molecular and mechanistic bases of which are incompletely defined. AIMS: The current studies were designed to test the hypothesis that heparin abrogates the expression or function of leucocyte-endothelial adherence molecules which are fundamental to the acute inflammatory response. METHODS: The effects of heparin on tumour necrosis factor alpha (TNF-alpha) induced leucocyte rolling, adhesion, and migration as well as vascular permeability were assessed in rat mesenteric venules using intravital microscopy. Expression of adhesion molecules was quantitated using a double radiolabelled monoclonal antibody (mAb) binding technique in vivo (P-selectin, intercellular cell adhesion molecule type 1 (ICAM-1), and vascular cell adhesion molecule 1 (VCAM-1)) or flow cytometry (CD11a, CD11b, and L-selectin). Ex vivo binding of heparin to neutrophils was assessed by flow cytometry. RESULTS:TNF-alpha induced a significant increase in leucocyte rolling, adhesion, and migration, and vascular permeability, coincident with a significant increase in expression of P-selectin, ICAM-1, and VCAM-1. Ex vivo assessment of blood neutrophils showed significant upregulation of CD11a and CD11b and significant downregulation of L-selectin within five hours of TNF-alpha administration. Heparin pretreatment significantly attenuated leucocyte rolling, adhesion, and migration but did not affect expression of cell adhesion molecules or vascular permeability elicited by TNF-alpha administration. Binding of heparin was significantly increased on blood neutrophils obtained five hours after TNF-alpha administration. Preincubation with an anti-CD11b mAb but not with an anti-CD11a or anti-L-selectin antibody significantly diminished heparin binding ex vivo. CONCLUSIONS: Our results support the concept that the anti-inflammatory effects of heparin involve attenuation of a CD11b dependent adherent mechanism.
Authors: G D'haens; S Van Deventer; R Van Hogezand; D Chalmers; C Kothe; F Baert; T Braakman; T Schaible; K Geboes; P Rutgeerts Journal: Gastroenterology Date: 1999-05 Impact factor: 22.682
Authors: B J Darien; J Fareed; K S Centgraf; A P Hart; P S MacWilliams; M K Clayton; H Wolf; K T Kruse-Elliott Journal: Shock Date: 1998-04 Impact factor: 3.454
Authors: W Fries; E Pagiaro; E Canova; P Carraro; G Gasparini; F Pomerri; A Martin; C Carlotto; E Mazzon; G C Sturniolo; G Longo Journal: Aliment Pharmacol Ther Date: 1998-03 Impact factor: 8.171
Authors: M Sans; J Panés; E Ardite; J I Elizalde; Y Arce; M Elena; A Palacín; J C Fernández-Checa; D C Anderson; R Lobb; J M Piqué Journal: Gastroenterology Date: 1999-04 Impact factor: 22.682
Authors: J Panés; S Pérez-del-Pulgar; M Casadevall; A Salas; P Pizcueta; J Bosch; D C Anderson; D N Granger; J M Piqué Journal: Hepatology Date: 1999-08 Impact factor: 17.425
Authors: L Benimetskaya; J D Loike; Z Khaled; G Loike; S C Silverstein; L Cao; J el Khoury; T Q Cai; C A Stein Journal: Nat Med Date: 1997-04 Impact factor: 53.440
Authors: M J Sanz; A Hartnell; P Chisholm; C Williams; D Davies; V B Weg; M Feldmann; M A Bolanowski; R R Lobb; S Nourshargh Journal: Blood Date: 1997-11-15 Impact factor: 22.113
Authors: D D Henninger; J Panés; M Eppihimer; J Russell; M Gerritsen; D C Anderson; D N Granger Journal: J Immunol Date: 1997-02-15 Impact factor: 5.422
Authors: Thangirala Sudha; Murat Yalcin; Hung-Yun Lin; Ahmed M Elmetwally; Tipu Nazeer; Thiruvengadam Arumugam; Patricia Phillips; Shaker A Mousa Journal: Cancer Lett Date: 2014-04-24 Impact factor: 8.679
Authors: S Baldus; J P Eiserich; A Mani; L Castro; M Figueroa; P Chumley; W Ma; A Tousson; C R White; D C Bullard; M L Brennan; A J Lusis; K P Moore; B A Freeman Journal: J Clin Invest Date: 2001-12 Impact factor: 14.808